Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

The prognostic value of tumor-informed minimal residual disease detection using circulating tumor DNA in first-line treatment of ovarian cancer

In 31 patients with stage II–IV ovarian cancer in complete remission after first-line surgery and platinum chemotherapy (no first-line PARP-inhibitor maintenance), landmark post-treatment MRD positivity was associated with shorter median PFS (5.8 vs 24.7 months, HR 6.678, P=0.01).

Gynecol OncolPubMed 39579602DOI 10.1016/j.ygyno.2024.11.002